RPH-001 (bevacizumab biosimilar) / R-Pharm, Alphamab - LARVOL DELTA

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - P2; N=36; Completed; Sponsor: Academic and Community Cancer Research United; Active, not recruiting ➔ Completed

Clinical • Trial completion • EGFR

Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer (clinicaltrials.gov) - P2; N=22; Active, not recruiting; Sponsor: National Cancer Institute (NCI); Trial completion date: Feb 2019 ➔ Aug 2020; Trial primary completion date: Feb 2019 ➔ Aug 2020

Clinical • Combination therapy • IO Biomarker • Trial completion date • Trial primary completion date

BEAT-MBM: Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases (clinicaltrials.gov) - P2; N=40; Not yet recruiting; Sponsor: M.D. Anderson Cancer Center

Clinical • Combination therapy • New P2 trial

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors (clinicaltrials.gov) - P1; N=58; Active, not recruiting; Sponsor: National Cancer Institute (NCI); Trial primary completion date: Dec 2019 ➔ Jun 2020

Trial primary completion date • BRAF

Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer Receiving FOLFOX and Bevacizumab (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: Anne Noonan; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer (clinicaltrials.gov) - P2; N=22; Not yet recruiting; Sponsor: National Cancer Institute (NCI)

Clinical • Combination therapy • IO Biomarker • New P2 trial

BEAT-MBM: Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases (clinicaltrials.gov) - P2; N=60; Recruiting; Sponsor: M.D. Anderson Cancer Center; N=40 ➔ 60

Clinical • Combination therapy • Enrollment change

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer (clinicaltrials.gov) - P2; N=78; Active, not recruiting; Sponsor: National Cancer Institute (NCI); Trial primary completion date: Dec 2019 ➔ Dec 2020

Clinical • Trial primary completion date

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - P2; N=70; Active, not recruiting; Sponsor: National Cancer Institute (NCI); Trial completion date: Oct 2019 ➔ May 2020

Trial completion date

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - P2; N=168; Active, not recruiting; Sponsor: National Cancer Institute (NCI); Trial primary completion date: Oct 2019 ➔ Jul 2020

Clinical • Trial primary completion date • BRAF

BACCI: Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer (clinicaltrials.gov) - P2; N=135; Active, not recruiting; Sponsor: Academic and Community Cancer Research United; Trial completion date: Nov 2022 ➔ Mar 2021; Trial primary completion date: Nov 2020 ➔ Mar 2019

Clinical • PD(L)-1 Biomarker • Trial completion date • Trial primary completion date

Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (clinicaltrials.gov) - P1; N=31; Not yet recruiting; Sponsor: Northwestern University

Clinical • New P1 trial

Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer Receiving FOLFOX and Bevacizumab (clinicaltrials.gov) - P1; N=20; Not yet recruiting; Sponsor: Anne Noonan

New P1 trial

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - P3; N=1038; Active, not recruiting; Sponsor: National Cancer Institute (NCI); Trial primary completion date: Mar 2019 ➔ Dec 2019

Clinical • Combination therapy • Trial primary completion date

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - P2; N=36; Active, not recruiting; Sponsor: Academic and Community Cancer Research United; N=60 ➔ 36; Trial completion date: Dec 2021 ➔ Dec 2019; Trial primary completion date: Jun 2020 ➔ Mar 2019

Clinical • Enrollment change • Trial completion date • Trial primary completion date

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer (clinicaltrials.gov) - P3; N=506; Active, not recruiting; Sponsor: National Cancer Institute (NCI); Completed ➔ Active, not recruiting

Clinical • Enrollment closed

Pharmacokinetic Equivalence and Safety Study of RPH-001 and Avastin® (clinicaltrials.gov) - P1; N=80; Completed; Sponsor: R-Pharm; Recruiting ➔ Completed

Clinical • Trial completion